The Huntington’s Disease Regulatory Science Consortium was formed with the goal of improving the regulatory path for emerging therapies for Huntington’s disease. This global initiative will facilitate collaboration among biopharma/technology industry partners, academic institutions, government agencies, and patient-advocacy organizations.
The 1st Spinocerebellar Ataxia (SCA) Global Conference proved an exciting time for the Ataxia community, with a goal to assemble a global consortium for clinical studies of the spinocerebellar ataxias, (SCAs).
IXICO sponsored the event and presented a poster: ''Development of a fully automated method for MRI volumetry in ataxia''
International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders.
As the industry continues to debate approaches to the long term solution to finding treatments in Alzheimer's disease, particularly following recent announcements of further late phase failures, IXICO is continuing in its work to support clinical research in these Therapeutic Areas through collaboration, partnership and innovation in technology that supports the increasing requirement for better data science.
The 14th Huntington’s Disease Therapeutics Conference provided a forum to review the significant progress in HD clinical development, learn about exciting new findings, and build a collaborative path forward to overcome the remaining challenges to accelerating the development of therapeutics that will substantially benefit HD families.
HAI 2019 will emphasize lively discussion of core controversies such as: what does the presence of brain amyloid mean, how should it be measured, how does it change, and what does it portend? Our discussions primarily spring from brief presentations by active investigators who will report on unpublished, cutting-edge research in human imaging of amyloid-beta and/or other biomarkers that pertain to Alzheimer’s-related disease.
11-17 of 17 results